Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
Differentiated thyroid cancer (DTC) usually has a good prognosis when treated conventionally with thyroidectomy, radioactive iodine (RAI) and thyroid-stimulating hormone suppression, but some tumors develop a resistance to RAI therapy, requiring alternative treatments. Sorafenib, lenvatinib and cabo...
Saved in:
Main Authors: | Anne Christine Kaae, Michael C. Kreissl, Marcus Krüger, Manfred Infanger, Daniela Grimm, Markus Wehland |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/d3e7b9e0c59342ffacfd6a407e6d6898 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report
by: Soji Toda, et al.
Published: (2021) -
Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
by: Yuki Zaizen, et al.
Published: (2021) -
Acne Inversa-like Lesions Induced by a Low Dose of Sorafenib
by: Javier Aubán-Pariente, et al.
Published: (2021) -
Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
by: Ke Y, et al.
Published: (2018) -
Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System
by: Skubalova Z, et al.
Published: (2021)